Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus

BACKGROUND: Diabetes mellitus (DM) increases the risk of TB disease and poor treatment outcomes such as delayed sputum culture conversion due to inadequate drug exposure. Therapeutic drug monitoring (TDM) has improved these outcomes in some settings. METHODS: To compare treatment outcomes in program...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkabab, Y., Warkentin, J., Cummins, J., Katz, B., Denison, B. M., Bartok, A., Khalil, A., Young, L. R., Timme, E., Peloquin, C. A., Ashkin, D., Houpt, E. R., Heysell, S. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904402/
https://www.ncbi.nlm.nih.gov/pubmed/36853114
http://dx.doi.org/10.5588/ijtld.22.0448
Descripción
Sumario:BACKGROUND: Diabetes mellitus (DM) increases the risk of TB disease and poor treatment outcomes such as delayed sputum culture conversion due to inadequate drug exposure. Therapeutic drug monitoring (TDM) has improved these outcomes in some settings. METHODS: To compare treatment outcomes in programs with routine TDM vs. programs that did not use TDM, we conducted a retrospective study among people with DM and TB at health departments in four US states. RESULTS: A total of 170 patients were enrolled (73 patients in the non-TDM group and 97 patients in the TDM group). Days to sputum culture conversion and total treatment duration were significantly shorter in the TDM group vs. the non-TDM group. In adjusted analyses, patients who underwent TDM were significantly more likely to achieve sputum culture conversion at 2 months (P = 0.007). CONCLUSION: TDM hastened microbiological cure from TB among people with DM and a high risk for poor treatment outcomes in the programmatic setting.

Ejemplares similares